Carrozzo I, Maule G, Gentile C, Umbach A, Ciciani M, Guidone D
Mol Ther. 2025; 33(3):970-985.
PMID: 39797401
PMC: 11897810.
DOI: 10.1016/j.ymthe.2025.01.011.
Singh K, Fronza R, Evens H, Chuah M, VandenDriessche T
Mol Ther Methods Clin Dev. 2024; 32(4):101365.
PMID: 39655309
PMC: 11626537.
DOI: 10.1016/j.omtm.2024.101365.
Feng Q, Li Q, Zhou H, Wang Z, Lin C, Jiang Z
MedComm (2020). 2024; 5(8):e672.
PMID: 39081515
PMC: 11286548.
DOI: 10.1002/mco2.672.
Jadlowsky J, Chang J, Spencer D, Warrington J, Levine B, June C
Cancer Immunol Res. 2024; 12(9):1132-1135.
PMID: 39018097
PMC: 11371504.
DOI: 10.1158/2326-6066.CIR-24-0482.
Xiao M, Damodaran A, Kumari B, Dickson E, Xing K, On T
Mol Cell. 2024; 84(13):2553-2572.e19.
PMID: 38917794
PMC: 11246229.
DOI: 10.1016/j.molcel.2024.05.024.
OliTag-seq enhances in cellulo detection of CRISPR-Cas9 off-targets.
Yang Z, Deng D, Gao Z, Zhang Z, Fu Y, Wen W
Commun Biol. 2024; 7(1):696.
PMID: 38844522
PMC: 11156888.
DOI: 10.1038/s42003-024-06360-w.
Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells.
Bulcaen M, Kortleven P, Liu R, Maule G, Dreano E, Kelly M
Cell Rep Med. 2024; 5(5):101544.
PMID: 38697102
PMC: 11148721.
DOI: 10.1016/j.xcrm.2024.101544.
CoCas9 is a compact nuclease from the human microbiome for efficient and precise genome editing.
Pedrazzoli E, Demozzi M, Visentin E, Ciciani M, Bonuzzi I, Pezze L
Nat Commun. 2024; 15(1):3478.
PMID: 38658578
PMC: 11043407.
DOI: 10.1038/s41467-024-47800-9.
Eukaryotic-driven directed evolution of Cas9 nucleases.
Ruta G, Ciciani M, Kheir E, Gentile M, Amistadi S, Casini A
Genome Biol. 2024; 25(1):79.
PMID: 38528620
PMC: 10962177.
DOI: 10.1186/s13059-024-03215-9.
Engineering of Cas12a nuclease variants with enhanced genome-editing specificity.
Chen P, Zhou J, Liu H, Zhou E, He B, Wu Y
PLoS Biol. 2024; 22(3):e3002514.
PMID: 38483978
PMC: 10965058.
DOI: 10.1371/journal.pbio.3002514.
Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome.
Pille M, Avila J, Park S, Le C, Xue H, Haerynck F
Mol Ther Methods Clin Dev. 2024; 32(1):101208.
PMID: 38414825
PMC: 10897892.
DOI: 10.1016/j.omtm.2024.101208.
Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics.
Lopes R, Prasad M
Front Bioeng Biotechnol. 2024; 11:1339189.
PMID: 38390600
PMC: 10883050.
DOI: 10.3389/fbioe.2023.1339189.
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calvino C, Ceballos C, Alfonso A, Jauregui P, Calleja-Cervantes M, San Martin-Uriz P
Front Immunol. 2023; 14:1270843.
PMID: 37795087
PMC: 10546312.
DOI: 10.3389/fimmu.2023.1270843.
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Agarwal S, Aznar M, Rech A, Good C, Kuramitsu S, Da T
Immunity. 2023; 56(10):2388-2407.e9.
PMID: 37776850
PMC: 10591801.
DOI: 10.1016/j.immuni.2023.09.001.
Evolutionary mining and functional characterization of TnpB nucleases identify efficient miniature genome editors.
Xiang G, Li Y, Sun J, Huo Y, Cao S, Cao Y
Nat Biotechnol. 2023; 42(5):745-757.
PMID: 37386294
DOI: 10.1038/s41587-023-01857-x.
Efficient precise integration of large DNA sequences with 3'-overhang dsDNA donors using CRISPR/Cas9.
Han W, Li Z, Guo Y, He K, Li W, Xu C
Proc Natl Acad Sci U S A. 2023; 120(22):e2221127120.
PMID: 37216515
PMC: 10235934.
DOI: 10.1073/pnas.2221127120.
An optimized SpCas9 high-fidelity variant for direct protein delivery.
Pedrazzoli E, Bianchi A, Umbach A, Amistadi S, Brusson M, Frati G
Mol Ther. 2023; 31(7):2257-2265.
PMID: 36905119
PMC: 10362380.
DOI: 10.1016/j.ymthe.2023.03.007.
Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor.
Amistadi S, Maule G, Ciciani M, Ensinck M, De Keersmaecker L, Ramalho A
Mol Ther. 2023; 31(6):1647-1660.
PMID: 36895161
PMC: 10277887.
DOI: 10.1016/j.ymthe.2023.03.004.
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.
Tao J, Bauer D, Chiarle R
Nat Commun. 2023; 14(1):212.
PMID: 36639728
PMC: 9838544.
DOI: 10.1038/s41467-023-35886-6.
disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study.
Doerfler A, Park S, Assini J, Youssef A, Saxena L, Yaseen A
Mol Ther Methods Clin Dev. 2022; 27:337-351.
PMID: 36381302
PMC: 9630778.
DOI: 10.1016/j.omtm.2022.10.009.